Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Multi-Cancer Early Detection Test Wins FDA Panel Backing for Approval

By LabMedica International staff writers
Posted on 24 Sep 2026

GRAIL’s Galleri multi-cancer early detection (MCED) test was reviewed by the Molecular and Clinical Genetics Devices Panel of the U. More...

S. Food and Drug Administration’s (FDA) Medical Devices Advisory Committee. The panel’s 10 voting members considered the test’s safety, effectiveness, and overall benefit–risk profile for screening multiple cancer types in adults aged 50 years and older. In three separate votes, the panel voted 7–2, with one abstention, that the benefits outweigh the risks; unanimously that the test is safe; and 6–4 that it is effective.

Galleri is designed to detect cancer-specific methylation patterns shared across multiple cancer types before symptoms appear, including cancers for which no recommended screening currently exists. When a cancer signal is detected, the test also predicts the likely Cancer Signal Origin to help guide subsequent diagnostic evaluation. Galleri is intended to complement, rather than replace, guideline-recommended cancer screening.

The test has been evaluated in large interventional and randomized controlled studies involving intended-use populations, including the U.S. Food and Drug Administration Investigational Device Exemption (IDE) PATHFINDER 2 study in North America and the NHS-Galleri trial in England. Across clinical studies, Galleri has detected approximately four to seven times more cancers than standard-of-care screening alone, with many Galleri-detected cancers identified at earlier stages while maintaining a low false-positive rate and high Cancer Signal Origin prediction accuracy. GRAIL has also submitted Galleri through the FDA’s premarket approval (PMA) pathway, representing the first PMA submission for an MCED test.

Galleri received Breakthrough Device designation in 2018, and GRAIL submitted its PMA application on January 29, 2026. The FDA convenes advisory committees to obtain independent expert advice and is not bound by their recommendations, although it considers them in final regulatory decisions. A final decision on the Galleri PMA is expected in the coming months.

“The Galleri test was developed to improve the effectiveness and efficiency of our national cancer screening program by adding multi-cancer early detection to recommended screening—helping find more cancers safely, when they may be easier and less costly to treat, and it still may be possible for a patient to receive treatment with curative intent,” said Josh Ofman, M.D., M.S.H.S., chief executive officer at GRAIL.

 "Today's vote reinforces the strength of Galleri's clinical evidence. We believe the panel's recommendations reaffirm a high evidence bar that GRAIL has set for a multi-cancer early detection test. GRAIL is committed to working with the FDA as it completes its review of Galleri, the first PMA submission for a multi-cancer early detection test," said Ofman. 

Related Links
Grail Inc


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.